{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:34:29Z","timestamp":1773297269564,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11912-020-0868-1","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T19:02:38Z","timestamp":1579546958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Emerging Role of Local Therapy in Metastatic Prostate Cancer"],"prefix":"10.1007","volume":"22","author":[{"given":"Nora","family":"Sundahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"issue":"6","key":"868_CR1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058\u201366.","journal-title":"Eur Urol"},{"issue":"1","key":"868_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","volume":"67","author":"N Fossati","year":"2015","unstructured":"Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67(1):3\u20136.","journal-title":"Eur Urol"},{"issue":"3","key":"868_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2014.04.009","volume":"66","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602\u20133.","journal-title":"Eur Urol"},{"issue":"24","key":"868_CR4","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(24):2835\u201342.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"868_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","volume":"67","author":"P Ost","year":"2015","unstructured":"Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852\u201363.","journal-title":"Eur Urol"},{"key":"868_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/1471-2407-14-671","volume":"14","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671.","journal-title":"BMC Cancer"},{"issue":"7069","key":"868_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u20137.","journal-title":"Nature."},{"issue":"8","key":"868_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrclinonc.2011.88","volume":"8","author":"SC Morgan","year":"2011","unstructured":"Morgan SC, Parker CC. Local treatment of metastatic cancer--killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011;8(8):504\u20136.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"868_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrc2621","volume":"9","author":"B Psaila","year":"2009","unstructured":"Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"868_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","volume":"15","author":"JT Erler","year":"2009","unstructured":"Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35\u201344.","journal-title":"Cancer Cell"},{"issue":"12","key":"868_CR11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/ncb1507","volume":"8","author":"S Hiratsuka","year":"2006","unstructured":"Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369\u201375.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"868_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cell.2008.01.046","volume":"133","author":"D Padua","year":"2008","unstructured":"Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66\u201377.","journal-title":"Cell."},{"issue":"4","key":"868_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","volume":"155","author":"FG Giancotti","year":"2013","unstructured":"Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155(4):750\u201364.","journal-title":"Cell."},{"key":"868_CR14","unstructured":"Gu\u017evi\u0107 M, Klein CA. The biology of cancer metastasis. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 117\u201328."},{"issue":"1","key":"868_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","volume":"16","author":"Q Liu","year":"2017","unstructured":"Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis. Mol Cancer. 2017;16(1):176.","journal-title":"Mol Cancer"},{"issue":"7547","key":"868_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353\u20137.","journal-title":"Nature."},{"key":"868_CR17","unstructured":"\u2022\u2022 Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England). 2018;392(10162):2353\u201366. Practice changing randomized controlled phase 3 trial showing that local radiotherapy improves overall survival in newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer."},{"key":"868_CR18","doi-asserted-by":"publisher","first-page":"c117","DOI":"10.1136\/bmj.c117","volume":"340","author":"X Sun","year":"2010","unstructured":"Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.","journal-title":"BMJ"},{"issue":"3","key":"868_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boeve","year":"2019","unstructured":"\u2022 Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410\u20138. Randomized controlled phase 3 trial investigating local radiotherapy to the prostate in newly diagnosed patients with metastatic hormone-sensitive prostate cancer.","journal-title":"Eur Urol"},{"issue":"1","key":"868_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"\u2022 Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol. 2019;76(1):115\u201324. Meta-analysis of the STAMPEDE and the HORRAD data, confirming that local radiotherapy improves overall survival in newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer.","journal-title":"Eur Urol"},{"key":"868_CR21","unstructured":"Cytoreductive prostatectomy versus cytoreductive prostate irradiation as a local treatment option for metastatic prostate cancer: a multicentric feasibility trial (LoMP II) 2018 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03655886."},{"key":"868_CR22","unstructured":"SWOG1802 Phase III Randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer [Available from: https:\/\/www.swog.org\/clinical-trials\/s1802."},{"issue":"15","key":"868_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"868_CR24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","volume":"10","author":"SC Formenti","year":"2009","unstructured":"Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718\u201326.","journal-title":"Lancet Oncol"},{"issue":"8","key":"868_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"key":"868_CR26","unstructured":"Ali A, Hoyle AP, James ND, Parker CC, Brawley CC, Attard G, Douis H, Mason M, Parmar MK, Sydes MR, Clarke NW, and the STAMPEDE investigators. Exploratory analysis of metastatic site and number in the STAMPEDE M1\/RT comparison. Presented at ESMO 2019."},{"issue":"5","key":"868_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"Piet Ost","year":"2018","unstructured":"\u2022 Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(5):446\u201353. Randomized phase 2 trial suggesting that local treatment of metastases in patients with hormone-sensitive oligometastatic prostate cancer might be beneficial.","journal-title":"Journal of Clinical Oncology"},{"issue":"10185","key":"868_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393(10185):2051\u20138.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"868_CR29","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672\u201382.","journal-title":"Lancet Oncol"},{"issue":"18","key":"868_CR30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(18):1558\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"868_CR31","doi-asserted-by":"crossref","unstructured":"Patel PH, Palma D, McDonald F, Tree AC. The Dandelion Dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clinical oncology (Royal College of Radiologists (Great Britain)). 2019.","DOI":"10.1016\/j.clon.2019.05.015"},{"issue":"7","key":"868_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312.","journal-title":"Lancet Oncol"},{"key":"868_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415.","journal-title":"Nature."},{"issue":"1","key":"868_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65\u201385.","journal-title":"CA Cancer J Clin"},{"key":"868_CR35","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"5","key":"868_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol. 2019;75(5):707\u201311.","journal-title":"Eur Urol"},{"issue":"4","key":"868_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","volume":"75","author":"G Vandekerkhove","year":"2019","unstructured":"Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, et al. Circulating tumor DNA abundance and potential utility in De novo metastatic prostate cancer. Eur Urol. 2019;75(4):667\u201375.","journal-title":"Eur Urol"},{"issue":"18","key":"868_CR38","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"issue":"5","key":"868_CR39","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ijc.31397","volume":"143","author":"J Belic","year":"2018","unstructured":"Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018;143(5):1236\u201348.","journal-title":"Int J Cancer"},{"issue":"4","key":"868_CR40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444\u201357.","journal-title":"Cancer Discov"},{"key":"868_CR41","doi-asserted-by":"crossref","unstructured":"Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7(312):312re10-re10.","DOI":"10.1126\/scitranslmed.aac9511"},{"issue":"1","key":"868_CR42","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41467-018-03573-6","volume":"9","author":"L Latonen","year":"2018","unstructured":"Latonen L, Afyounian E, Jylh\u00e4 A, N\u00e4ttinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9(1):1176.","journal-title":"Nat Commun"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0868-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:36:55Z","timestamp":1611016615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0868-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0868-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"20 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nora Sundahl has received travel support from Bayer, MSD, Bristol-Myers Squibb, and Astellas.Alison Tree has received research funding from Elekta, Accuray, and MSD; and has received travel support and honoraria from Janssen, Bayer, Astellas, Ferring, Bayer, and Elekta.Chris Parker has received compensation from AAA Pharmaceutical, Bayer, and Janssen for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"2"}}